Search Results
Your search for The ASCO matches 21740 pages
Showing 21051 - 21100FDA Advisory Committee Votes Against Accelerated Approval for Olaparib in Ovarian Cancer
The U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 11 to 2 that current evidence from clinical studies does not support an accelerated approval for use of olaparib as a maintenance treatment for women with platinum-sensitive relapsed ovarian cancer who have...
St. Jude Children’s Research Hospital Appoints James R. Downing, MD, as CEO
St. Jude Children’s Research Hospital announced the appointment of James R. Downing, MD, as its new CEO, effective July 15, 2014. Dr. Downing most recently has served as the Deputy Director, Executive Vice President and Scientific Director of the hospital. He succeeds William E. Evans,...
Synthetic Triterpenoids Show Promise in Preventing Colitis-Associated Colon Cancer in Preclinical Study
Researchers from Case Western Reserve and Dartmouth have shown that a class of small antioxidant molecules carries promise for suppressing colon cancer associated with colitis. These preclinical findings, published in the Journal of Clinical Investigation, offer hope that physicians ultimately will ...
BPA Stimulates Growth of Breast Cancer Cells, Diminishes Effect of Treatment
Bisphenol A (BPA), a chemical commonly used in plastics, appears to increase the proliferation of breast cancer cells, according to Duke Medicine researchers presenting at ICE/ENDO 2014, the annual joint meeting of the International Society of Endocrinology and the Endocrine Society in Chicago. The ...
Early Evidence Suggests Proton Therapy May Offer Safe, Long-Term Treatment for Hodgkin Lymphoma
Despite some success in treating patients with Hodgkin lymphoma, many patients may experience late effects of radiation therapy and chemotherapy treatment, including the possible onset of breast cancer or heart disease. A study by Hoppe et al from the University of Florida Proton Therapy Institute...
New Tool Predicts Financial Pain for Cancer Patients
In an online report in the journal Cancer, a team of University of Chicago cancer specialists have described the first tool—11 questions, assembled and refined from conversations with more than 150 patients with advanced cancer—to measure a patient’s risk for, and ability to...
Development of Orteronel for Prostate Cancer Voluntarily Discontinued by Takeda
Takeda Pharmaceutical Company Limited announced today that it has voluntarily decided to end the development program for orteronel (TAK-700), an investigational oral, nonsteroidal, selective inhibitor of 17,20-lyase, for prostate cancer. The decision follows the results of two phase III...
Racial Disparities in Sentinel Lymph Node Biopsy in Women With Breast Cancer
A study by Black et al from The University of Texas MD Anderson Cancer Center, Houston, found that the use of sentinel lymph node biopsy to stage early breast cancer increased in both black and white women from 2002 to 2007, but the rates remained lower in black than white patients, a disparity...
Diversity of Intestinal Tract Bacteria Associated With Mortality Outcomes After Stem Cell Transplant, Study Shows
New research published online in Blood suggests that the diversity of bacteria in the gastrointestinal tract of patients receiving stem cell transplants may be an important predictor of their post-transplant survival. Potential Connections Previous studies have shown that the intensive treatment...
Survey Finds Booming E-Cigarette Online Market
Researchers at the University of California, San Diego, School of Medicine have completed the first comprehensive survey of e-cigarettes for sale online, and the results, they believe, underscore the complexity in regulating the rapidly growing market for the electronic nicotine delivery devices....
Lung-MAP Launches: First Precision Medicine Trial From National Clinical Trials Network
A unique public-private collaboration among the National Cancer Institute (NCI), SWOG Cancer Research, Friends of Cancer Research, the Foundation for the National Institutes of Health (FNIH), five pharmaceutical companies (Amgen, Genentech, Pfizer, AstraZeneca, and AstraZeneca’s global...
Brain Tumor Risk Greater in Women Who Begin Menstruation at Older Age, Study Reports
Women who begin menstruation at an older age have a significantly increased risk of developing a brain tumor, a Moffitt Cancer Center study shows. The results are part of a large multicenter study to determine potential risk factors associated with the development of glioma and meningioma. The...
FDA Approves Radioactive Diagnostic Imaging Agent to Help Determine the Extent of Head and Neck Cancer in the Body
The U.S. Food and Drug Administration today approved a new use for technetium 99m tilmanocept (Lymphoseek Injection), a radioactive diagnostic imaging agent used to help doctors determine the extent to which squamous cell carcinoma has spread in the body’s head and neck region. In 2013,...
FDA Approves Magnetic Resonance Contrast Agent for Evaluation of Breast Cancer
The U.S. Food and Drug Administration has approved a new indication for gadobutrol (Gadavist) injection for intravenous use with magnetic resonance imaging (MRI) of the breast to assess the presence and extent of malignant breast disease. The approval is based on priority review of two multicenter...
Barbara L. McAneny, MD, To Serve as Chair of the AMA Board of Trustees
Barbara L. McAneny, MD, a practicing oncologist from Albuquerque, New Mexico, has been re-elected to the Board of Trustees of the American Medical Association (AMA) and will assume the position of Board Chair when the trustees gather for their first postelection meeting. Dr. McAneny, who has...
Mammography Has Led to Fewer Late-Stage Breast Cancers, Study Finds
In the past 30 years, since mammography was introduced, late-stage breast cancer incidence has decreased by 37%, a new study published in Cancer has found. The analysis by Helvie et al took into account an observed underlying trend of increased breast cancer incidence present since the 1940s....
ASCO 2014: Stopping Statins Is Safe and Can Improve Quality of Life for Patients With Cancer Near the End of Life
Stopping statin therapy is safe for patients with cancer who have a life expectancy of less than 1 year, according to a randomized study reported at the 2014 ASCO Annual Meeting in Chicago (Abstract LBA9514). Discontinuing statins did not shorten survival and provided a number of important...
ASCO 2014: Goserelin Helps Preserve Fertility Among Women Receiving Chemotherapy for Hormone Receptor–Negative Breast Cancer
Adding goserelin (Zoladex) to standard chemotherapy may be an effective method of preserving fertility among women with early-stage hormone receptor–negative breast cancer, according to findings from a federally funded phase III clinical trial. In the S0230/POEMS study, reported at the 2014...
ASCO 2014: Starting Palliative Care Support for Family Caregivers at the Time of Cancer Diagnosis Improves Quality of Life
Introducing a palliative care support program for caregivers of patients with advanced cancer at or near the time patients are diagnosed provides greater benefits than delayed palliative care services, according to results of the ENABLE III study reported at the 2014 ASCO Annual Meeting in Chicago...
ASCO 2014: Enzalutamide Before Chemotherapy Prolongs Progression-Free and Overall Survival in Metastatic Prostate Cancer
The androgen receptor inhibitor enzalutamide (Xtandi) has been shown to prolong survival in men with metastatic castration-resistant prostate cancer with progressive disease after chemotherapy. In the phase III PREVAIL trial reported in The New England Journal of Medicine, Beer et al found that...
ASCO 2014: Women With Breast Cancer and Bone Metastasis Can Safely Scale Back Frequency of Zoledronic Acid Dosing
Findings from a phase III randomized study suggest that women with breast cancer and bone metastasis who have received at least nine doses of zoledronic acid over the previous year can safely scale back dosing from every 4 weeks to every 12 weeks without compromising the effectiveness of the...
ASCO 2014: Lower-Dose Radiation May Reduce Long-Term Side Effects Without Compromising Survival in Certain HPV-Positive Head and Neck Cancers
According to a phase II study, customizing radiation doses based on response to induction chemotherapy and other prognostic factors may allow lower doses of radiation therapy to be administered to some patients with human papillomavirus (HPV)-positive oropharyngeal cancer without compromising...
ASCO 2014: Ipilimumab/Nivolumab Combination Achieves Long-Term Survival for Patients With Advanced Melanoma
Concurrent treatment with ipilimumab (Yervoy) and nivolumab resulted in a 2-year survival rate of 79% for patients with advanced melanoma. “While this is a small trial, that is very impressive 2-year survival data,” noted Mario Sznol, MD, at a press briefing on progress in immunotherapy ...
ASCO 2014: PD-1–Targeting Antibody Pembrolizumab Produces Long-Term Responses in Patients With Metastatic Melanoma
Findings from a large phase I study of 411 patients with advanced melanoma show that the PD-1–targeting antibody pembrolizumab (MK-3475) produced responses in 34% of patients, including 28% of patients whose disease progressed on prior treatment with ipilimumab (Yervoy). Among those who...
ASCO 2014: Adjuvant Ipilimumab Significantly Improves Recurrence-Free Survival in Patients With High-Risk Stage III Melanoma
Adjuvant therapy with ipilimumab (Yervoy) for patients with high-risk stage III melanoma significantly improved recurrence-free survival, the primary endpoint of the phase III EORTC 18071/CA 184-029 study. Patients randomly assigned to receive ipilimumab had a 9-month absolute improvement in...
Smokers With BRCA2 Mutation Have Increased Risk of Developing Lung Cancer
Around a quarter of smokers who carry a mutation in the BRCA2 gene will develop lung cancer at some point in their lifetime, a large-scale, international study reveals. Scientists described a previously unknown link between lung cancer and a particular BRCA2 mutation, which occurs in around 2% of...
ASCO 2014: Cediranib Plus Olaparib Significantly Increases Progression-Free Survival in Women With Recurrent Ovarian Cancer
The combination of two investigational oral drugs, the PARP inhibitor olaparib and the antiangiogenic drug cediranib, significantly extended progression-free survival and increased the overall response rate compared to olaparib alone in a phase II study among women with recurrent,...
ASCO 2014: Lenvatinib Yields High Response Rates, Delays Progression in Patients With Radioiodine-Resistant Differentiated Thyroid Cancer
A phase III, multicenter, double-blind, placebo-controlled study found that the oral targeted drug lenvatinib is highly effective among patients with differentiated thyroid cancer resistant to standard radioiodine therapy. “The main result is an extraordinary improvement in progression-free...
ASCO 2014: Ceritinib Shows Rapid, Durable Response in ALK-Positive NSCLC
In a phase I study, ceritinib (Zykadia) was found to shrink tumors in patients with anaplastic lymphoma kinase (ALK)-positive non–small cell lung cancer (NSCLC), regardless of whether patients had received previous treatment with an ALK inhibitor. The study was presented at the 2014 ASCO...
ASCO 2014: Adding Lapatinib to Adjuvant Trastuzumab Does Not Improve Outcomes in Early-Stage HER2-Positive Breast Cancer
A large phase III study, ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation), found no statistically significant differences in 4-year disease-free survival among women with early HER2-positive breast cancer who received adjuvant treatment that combined the HER2-targeted drugs...
ASCO 2014: Chemotherapy Plus Either Bevacizumab or Cetuximab Results in Similar Survival Benefits in Metastatic Colorectal Cancer
Bevacizumab (Avastin) plus chemotherapy and cetuximab (Erbitux) plus chemotherapy produced equal survival benefits for patients with metastatic colorectal cancer and no KRAS mutations, according to results from a large federally funded phase III study presented at the 2014 ASCO Annual Meeting...
ASCO 2014: Adding Docetaxel to Androgen-Deprivation Therapy Significantly Improves Survival in Hormone-Sensitive Prostate Cancer
The addition of docetaxel to androgen-deprivation therapy extended survival for men with newly diagnosed hormone-sensitive prostate cancer by more than 13 months in the National Cancer Institute–led phase III E3805 study. The survival benefit was even greater for men with high-volume disease. ...
ASCO 2014: Adjuvant Exemestane With Ovarian Function Suppression Better at Preventing Breast Cancer Recurrence Than Tamoxifen
A joint analysis of two phase III trials demonstrated that the aromatase inhibitor exemestane more effectively prevents breast cancer recurrences than tamoxifen when either was given with ovarian function suppression to premenopausal women with hormone-sensitive cancers. Exemestane plus ovarian...
ASCO 2014: Addition of Chemotherapy to Radiotherapy Improves Survival in Low-Grade Glioma
In a long-term follow-up analysis of RTOG 9802, the addition of PCV (procarbazine [Matulane], lomustine [CeeNu], and vincristine) to radiotherapy prolonged both progression-free survival and overall survival in adult patients with low-grade glioma. The findings were reported at the 2014 ASCO Annual ...
ASCO 2014: Ibrutinib Significantly Delays Disease Progression and Extends Survival in Relapsed CLL
Early findings from the phase III RESONATE study indicate that ibrutinib (Imbruvica) produces durable tumor responses and marked improvement in survival over standard ofatumumab (Arzerra) for patients with relapsed chronic lymphocytic leukemia (CLL). “With ibrutinib, about 80% of patients...
ASCO 2014: Second-Line Treatment With Ramucirumab Plus Standard Docetaxel Extends Overall Survival in Advanced Lung Cancer
Patients with stage IV non–small cell lung cancer (NSCLC) who relapsed after initial platinum-based therapy experienced extended overall survival with a combination of the antiangiogenic agent ramucirumab (Cyramza) and standard chemotherapy with docetaxel, compared to patients receiving...
ASCO 2014: Investigational Anti–PD-L1 Antibody Demonstrates Promising Activity in Certain Patients With Metastatic Bladder Cancer
In a phase I study, the investigational anti–programmed death-ligand 1 (PD-L1) monoclonal antibody MPDL3280A demonstrated promising overall response rates in patients with previously treated metastatic urothelial bladder cancer whose tumors were characterized as PD-L1–positive. The ...
ASCO 2014: Bortezomib Combination Significantly Improves Progression-Free Survival in Newly Diagnosed Mantle Cell Lymphoma
An international, randomized phase III study found that replacing vincristine with bortezomib (Velcade) in R-CHOP (rituximab [Rituxan] plus cyclophosphamide, doxorubicin, vincristine, and prednisone) significantly improved outcomes in newly diagnosed patients with mantle cell lymphoma who were...
ASCO 2014: Patients With Metastatic Colon Cancer Respond to New Combination Therapy, Phase IB Study Shows
In a new study presented at the 2014 ASCO Annual Meeting in Chicago (Abstract 3516), researchers from The University of Texas MD Anderson Cancer Center found patients with advanced colorectal cancer responded well to a combination therapy of the drugs vemurafenib (Zelboraf), cetuximab (Erbitux),...
ASCO 2014: Women With BRCA Mutations Report Significant Side Effects Following Risk-Reducing Salpingo-Oophorectomy
The majority of women with BRCA1 and BRCA2 mutations experience sexual dysfunction, menopausal symptoms, cognitive and stress issues, and poor sleep following risk-reducing salpingo-oophorectomy, according to results of a new study from the Abramson Cancer Center and the Perelman School of Medicine ...
ASCO 2014: Men Who Receive Radiation Therapy for Prostate Cancer Have Increased Long-Term Risk of Bladder or Rectal Cancer
Men with prostate cancer generally have an excellent prognosis, but questions remain about the risk of second primary malignancies after initial therapy for localized disease. According to a new study presented at the 2014 ASCO Annual Meeting in Chicago (Abstract 5034), although the overall risk of ...
Study Identifies Risk of Chemotherapy-Related Hospitalization for Early-Stage Breast Cancer Patients
Oncologists now have a new understanding of the toxicity levels of specific chemotherapy regimens used for women with early-stage breast cancer, according to research from The University of Texas MD Anderson Cancer Center. The retrospective study, reported in the Journal of Clinical Oncology by...
FDA Approves Palonosetron Hydrochloride to Prevent Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients
The U.S. Food and Drug Administration (FDA) has approved palonosetron hydrochloride (Aloxi) injection for the prevention of acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy, in children aged 1...
ASCO Guideline Update Recommends Tamoxifen for Up to 10 Years for Women With Nonmetastatic Hormone Receptor–Positive Breast Cancer
The American Society of Clinical Oncology (ASCO) has issued an update to its clinical practice guideline on the use of adjuvant endocrine therapy for women with stage I to III hormone receptor–positive breast cancer. The guideline was published in the Journal of Clinical Oncology. Duration...
Gene Mutation Found for Aggressive Form of Pancreatic Cancer
Researchers have identified a mutated gene common to adenosquamous carcinoma tumors, the first known unique molecular signature for this rare, but particularly virulent, form of pancreatic cancer. The findings by Liu et al are published in Nature Medicine. Pancreatic cancer is the fourth leading...
FDA Approves Panitumumab Plus FOLFOX for Wild-Type KRAS Metastatic Colorectal Cancer
The U.S. Food and Drug Administration (FDA) has approved panitumumab (Vectibix) for use in combination with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as first-line treatment in patients with wild-type KRAS (exon 2) metastatic colorectal cancer. This approval converts the accelerated...
Majority of Women Undergoing Contralateral Prophylactic Mastectomy Have No Major Risk Factors for Developing Cancer in Both Breasts
Patients deciding to undergo contralateral prophylactic mastectomy as part of initial treatment for breast cancer is a growing challenge in the management of the disease. Removing the unaffected breast has not been shown to increase survival, and the more aggressive procedure is associated with...
Supportive Tumor Tissue Surrounding Cancer Cells Hinders Pancreatic Cancer Progression, Preclinical Study Reports
Fibrous tissue long suspected of making pancreatic cancer worse actually supports an immune attack that slows tumor progression but cannot overcome it, scientists at The University of Texas MD Anderson Cancer Center reported in the journal Cancer Cell. “This supportive tissue that’s...
The Cancer Community Mourns the Passing of Selma Schimmel
The cancer community is mourning the death of Selma Schimmel who passed away on May 21, 2014, from malignant psoas syndrome, a complication of ovarian cancer. Ms. Schimmel died at Providence Tarzana Medical Center near her home in Los Angeles, California. She was 59. A tireless and fierce advocate ...
Study Uses Comprehensive Genomic Tumor Testing to Match Lung Cancer Patients With Targeted Therapies
In a recent study by the Lung Cancer Mutation Consortium (LCMC), investigators incorporated tumor genotyping into therapeutic decision-making for patients with lung adenocarcinomas. An oncogenic driver was detected in 64% of tumors from patients in this study. According to data from this study...
